IP Library Patent Application 12243343
Patent Application
App. No. 12/243,343

Toric Ophthalimc Lenses Having Selected Spherical Aberration Characteristics

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/243,343
Abstract

A toric ophthalmic lens having substantially zero spherical aberration for a first circular aperture having a first diameter and substantially zero spherical aberration for a second circular aperture having a second diameter, the first diameter being at least 4 mm and the second diameter being at least 3 mm, the first diameter being at least 0.5 mm larger than the second diameter. A series of ophthalmic lenses, each lens comprising a same spherical power as the other lenses in the set, and a unique cylindrical power, each lens comprising (i) a first toric surface, and (ii) a second surface, at least one of the first surface and the second surface being aspheric in a meridian, the lens having substantially zero spherical aberration for all circular optical zone diameters less than 4 mm.

Claims (25)

1 . A toric ophthalmic lens having substantially zero spherical aberration for a first circular aperture having a first diameter and substantially zero spherical aberration for a second circular aperture having a second diameter, the first diameter being at least 4 mm and the second diameter being at least 3 mm, the first diameter being at least 0.5 mm larger than the second diameter.

2 . The lens of claim 1 , wherein the substantially zero spherical aberration for the first aperture and the second aperture is achieved for 546 nm light.

3 . The lens of claim 1 , wherein the first diameter is at least 4.5 mm and the second diameter being at least 3.5 mm,

4 . The lens of claim 1 , wherein the first aperture and the second aperture both have spherical aberration magnitudes that are less than 1/10 of wave.

5 . The lens of claim 1 , wherein the lens has a posterior optical zone and an anterior optical zone, at least one of the posterior optical zone and the anterior optical zone being toric, the toric optical zone being biaspheric.

6 . The lens of claim 1 , wherein the lens has a posterior optical zone and an anterior optical zone, at least one of the posterior optical zone and the anterior optical zone being toric, at least one meridian of the toric optical zone comprises even-powered aspheric terms.

7 . The lens of claim 6 , wherein at least one meridian of the toric optical zone comprises only even-powered aspheric terms.

8 . The lens of claim 1 , wherein the lens is an intraocular lens.

9 . The lens of claim 1 , wherein the lens is a contact lens.

10 . An ophthalmic lens, comprising:

a first toric surface; and

a second surface, at least one of the first surface and the second surface being aspheric in a meridian, the lens having substantially zero spherical aberration for all circular optical zone diameters less than 4 mm.

11 . The lens of claim 10 , wherein the substantially zero spherical aberration is achieved for 546 nm light.

12 . The lens of claim 10 , wherein the lens has substantially zero spherical aberration for all circular optical zone diameters less than 4.5 mm.

13 . The lens of claim 10 , wherein the lens has substantially zero spherical aberration for all circular optical zone diameters less than 5.0 mm.

14 . The lens of claim 10 , wherein the spherical aberration has a magnitude of less than 1/20 of wave for all circular optical zone diameters less than 4 mm.

15 . The lens of claim 10 , wherein the meridian is a meridian of a toric surface.

16 . The lens of claim 10 , wherein the meridian is a meridian of a circularly symmetric surface.

17 . The lens of claim 10 , wherein the toric surface is biaspheric.

18 . The lens of claim 10 , wherein at least one meridian of the toric surface comprises even-powered aspheric terms.

19 . The lens of claim 18 , wherein the toric surface comprises only even-powered aspheric terms.

20 . The lens of claim 10 , wherein at least one meridian of the toric surface comprises only odd-powered aspheric terms.

21 . The lens of claim 10 , wherein the lens is an intraocular lens.

22 . The lens of claim 10 , wherein the lens is a contact lens.

23 . A series of ophthalmic lenses, each lens comprising a same spherical power as the other lenses in the series, and a unique cylindrical power, each lens comprising (i) a first toric surface, and (ii) a second surface, at least one of the first surface and the second surface being aspheric in a meridian, the lens having substantially zero spherical aberration for all circular optical zone diameters less than 4 mm.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Nov 18, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM, INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE
Reel/Frame 021849/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2008
From: KINGSTON, AMANDA C.; ALTMANN, GRIFFITH E.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 021801/0373 →